1. Search Result
Search Result
Results for "

Anticoagulants

" in MCE Product Catalog:

50

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

1

Inhibitory Antibodies

9

Natural
Products

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-106561
    Tioclomarol

    Others Cardiovascular Disease
    Tioclomarol, a coumarin anticoagulant, is a vitamin K antagonist.
  • HY-14936
    Sofigatran

    MCC-977

    Thrombin Cardiovascular Disease
    Sofigatran (MCC-977) is an orally active factor IIa (thrombin) inhibitor, acts as an anticoagulant. Sofigatran is used for the research of cardiovascular disease.
  • HY-111186
    Flocoumafen

    WL 108366

    Others Cardiovascular Disease
    Flocoumafen (WL 108366), a second-generation anticoagulant rodenticide (ARs), belongs to the family of vitamin K antagonist (VKA) molecules.
  • HY-P1929
    Bivalirudin

    Thrombin Cardiovascular Disease
    Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention.
  • HY-17567C
    Heparin sodium salt (MW 15kDa)

    Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)

    Thrombin Factor Xa Autophagy Cardiovascular Disease
    Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
  • HY-132179
    Fucoidan

    Glucosidase Cancer Metabolic Disease Cardiovascular Disease
    Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities.
  • HY-14853
    Darexaban

    YM150

    Factor Xa Ser/Thr Protease Cardiovascular Disease
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects.
  • HY-10274
    Dabigatran etexilate

    BIBR 1048

    Thrombin Cardiovascular Disease
    Dabigatran etexilate (BIBR 1048) is an orally active prodrug of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
  • HY-10274A
    Dabigatran etexilate mesylate

    BIBR 1048MS; Dabigatran etexilate methanesulfonate

    Thrombin Cardiovascular Disease
    Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
  • HY-150682
    FXIa-IN-9

    Factor Xa Cardiovascular Disease
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism.
  • HY-N7671
    Euphorbetin

    Others Cardiovascular Disease
    Euphorbetin exhibits anticoagulant activities.
  • HY-B1014
    Acenocoumarol

    Others Cardiovascular Disease
    Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist.
  • HY-B0325
    Phenindione

    Rectadione

    Others Cardiovascular Disease
    Phenindione is an anticoagulant which functions as a Vitamin K antagonist.
  • HY-B1610
    Sodium citrate dihydrate

    Trisodium citrate dihydrate; Citric acid trisodium salt dihydrate

    Bacterial Infection Cardiovascular Disease
    Sodium citrate dehydrate is an anticoagulant and also used as a buffer and food preservatives.
  • HY-10787
    Ximelagatran

    H 376/95

    Thrombin Cardiovascular Disease
    Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
  • HY-B0917
    Bromindione

    Fluidane; Halinone

    Others Cardiovascular Disease
    Bromindione is a potent, long-acting, inandione-derived, oral anticoagulant compound.
  • HY-17378
    Dabigatran (ethyl ester)

    Thrombin Cardiovascular Disease
    Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
  • HY-19691
    Idraparinux sodium

    SANORG 34006; SR-34006

    Thrombin Cardiovascular Disease
    Idraparinux (sodium) is a polymethylated synthetic pentasaccharide known to interact with the antithrombin III and act as anticoagulant.
  • HY-A0145
    Phenprocoumon

    Others Others
    Phenprocoumon is a coumarin derivative that acts as a long acting oral anticoagulant and an antagonist of vitamin K.
  • HY-B0918
    Chlorindione

    Chlophenadione; Indaliton; G-25766

    Others Cardiovascular Disease
    Chlorindione (Chlophenadione) is a potent anticoagulant. Chlorindione also is a vitamin K1 antagonist.
  • HY-B0924
    Anisindione

    Others Cardiovascular Disease
    Anisindione is a synthetic anticoagulant, prevents the formation of active procoagulation factors II, VII, IX, and X.
  • HY-N0228
    Scoparone

    Others Cardiovascular Disease Cancer
    Scoparone is isolated from Artemisia capillaris, has anticoagulant, vasorelaxant antioxidant, anti-inflammatory activities.
  • HY-10787S
    Ximelagatran-d11

    H 376/95-d11

    Thrombin Cardiovascular Disease
    Ximelagatran-d11 (H 376/95-d11) is the deuterium labeled Ximelagatran. Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
  • HY-17567B
    Heparin Lithium salt

    Thrombin Autophagy Cardiovascular Disease
    Heparin Lithium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII). Heparin Lithium salt significantly inhibits exosome-cell interactions.
  • HY-107911
    Protamine sulfate

    Thrombin Metabolic Disease
    Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer.
  • HY-132587
    Fitusiran

    ALN-AT3SC; SAR439774

    Factor Xa Others
    Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
  • HY-17567
    Heparin

    Thrombin Autophagy Endogenous Metabolite Cardiovascular Disease
    Heparin is a highly sulfated glycosaminoglycan,that is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Heparin significantly inhibits exosome-cell interactions.
  • HY-10273
    Atecegatran metoxil

    AZD0837; Atecegatran fexenetil

    Thrombin Cardiovascular Disease
    Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct thrombin inhibitor.
  • HY-137431
    Asundexian

    BAY-2433334

    Factor Xa Cardiovascular Disease
    Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM.
  • HY-10264B
    Edoxaban tosylate monohydrate

    DU-176b monohydrate

    Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.
  • HY-10264C
    Edoxaban hydrochloride

    DU-176 hydrochloride

    Factor Xa Thrombin Cardiovascular Disease
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research.
  • HY-10264
    Edoxaban

    DU-176

    Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
  • HY-10264A
    Edoxaban tosylate

    DU-176b

    Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research.
  • HY-17567A
    Heparin sodium salt

    Sodium heparin; Sodium heparinate

    Thrombin Factor Xa Autophagy Cardiovascular Disease
    Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
  • HY-B0190A
    Nafamostat mesylate

    FUT-175

    Ser/Thr Protease Apoptosis SARS-CoV Cardiovascular Disease Cancer
    Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat mesylate supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat mesylate blocks activation of SARS-CoV-2..
  • HY-B0190
    Nafamostat

    Ser/Thr Protease Apoptosis SARS-CoV Cardiovascular Disease
    Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2.
  • HY-B0190B
    Nafamostat hydrochloride

    Ser/Thr Protease Apoptosis SARS-CoV Cardiovascular Disease
    Nafamostat hydrochloride, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat hydrochloride supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat hydrochloride blocks activation of SARS-CoV-2..
  • HY-10163
    Dabigatran

    BIBR 953; BIBR 953ZW

    Thrombin Cardiovascular Disease
    Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
  • HY-N2853
    D-α-Tocopherylquinone

    α-Tocopherylquinone

    Others Cancer
    D-α-Tocopherylquinone (α-Tocopherylquinone) is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is a oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant.
  • HY-134686
    Edoxaban impurity 4

    Factor Xa Thrombin Cardiovascular Disease
    Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
  • HY-N1196
    Suberosin

    NF-κB Inflammation/Immunology
    Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB.
  • HY-105240
    Delparantag

    PMX-60056

    Factor Xa Cardiovascular Disease
    Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH.
  • HY-10277
    Odiparcil

    SB-424323

    Thrombin Cardiovascular Disease
    Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .
  • HY-10163S
    Dabigatran-d4

    BIBR 953-d4; BIBR 953ZW-d4

    Thrombin Cardiovascular Disease
    Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
  • HY-122704A
    Surfen dihydrochloride

    Aminoquincarbamide dihydrochloride

    FGFR HSV VEGFR Infection
    Surfen dihydrochloride is a potent HS (heparan sulfate) antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins. Surfen affects sulfation of heparin and inhibits degradation by heparin lyases. Surfen inhibits FGF2 binding and signaling. Surfen inhibits cell attachment, and virus infection.
  • HY-10163S1
    Dabigatran-d3

    BIBR 953-d3; BIBR 953ZW-d3

    Thrombin Cardiovascular Disease
    Dabigatran-d3 (BIBR 953-d3) is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
  • HY-10163S3
    Dabigatran-13C,d3

    BIBR 953-13C,d3; BIBR 953ZW-13C,d3

    Thrombin Cardiovascular Disease
    Dabigatran-13C,d3 is the 13C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
  • HY-N6856
    4-Hydroxycoumarin

    Endogenous Metabolite Bacterial Infection
    4-Hydroxycoumarin, a coumarin derivative, is one of the most versatile heterocyclic scaffolds and is frequently applied in the synthesis of various organic compounds. 4-Hydroxycoumarin possesses both electrophilic and nucleophilic properties. 4-Hydroxycoumarin derivatives are employed as the anticoagulant, antibacterial, antifungal, antiviral, antitumor, antiprotozoal, insecticidal, antimycobacterial, antimutagenic, antioxidant, anti-inflammatory agents, HIV protease inhibitors and tyrosine kinase inhibitors.
  • HY-109509
    Enoxaparin

    PK 10169; Enoxaparin sodium; Lovenox

    Factor Xa Thrombin SARS-CoV Infection Inflammation/Immunology Neurological Disease Cardiovascular Disease
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.
  • HY-10264S
    Edoxaban-d6

    DU-176-d6

    Factor Xa Thrombin Cardiovascular Disease
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment.